Abstract Library

#4242 Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

Introduction: Everolimus and Sunitinib are often used consecutively for advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET), but to date no data on the optimal sequence is available.

Conference:

Presenting Author: Islam O

Authors: Islam O, van de Vyver G, Verslype C, Borbath I, Decaestecker J,

Keywords: pNEN, Everolimus, Sunitinib, mPFS, mOS, AEs,

#4237 Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumor pAtients (SAUNA trial) – Study protocol for a bi-national, multi-center, open-label, randomised, pragmatic clinical trial

Introduction: Advanced gastroenteropancreatic neuroendocrine tumors (GEP NET) are treated with targeted therapy or peptide receptor radionuclide therapy (PRRT) (177Lu-DOTATATE) upon progression under somatostatin analogues (SSA). SSA are continued life-long in functional NET, but the benefit of SSA continuation in non-functional NET is unclear. Due to ongoing activity of the somatostatin receptor pathway in GEP NET progressing on SSA, we hypothesize an added efficacy of SSA during second-line therapy.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Kuiper J, Borbath I, Dercksen W, Deroose C,

Keywords: somatostatin analogues, SSA, everolimus, sunitinib, peptide receptor radionuclide therapy, PRRT, quality of life, QoL, gastroenteropancreatic neuroendocrine tumor, GEP NET,

#3998 Selective internal radiation therapy for neuroendocrine liver metastases: Efficacy, safety and prognostic factors – A retrospective single institution study

Introduction: Selective internal radiation therapy (SIRT) has shown good results in unresectable liver metastases from neuroendocrine neoplasms (NENLMs) with a high disease control rate (DCR) reported (Braat et al., 2019).

Conference:

Presenting Author: Borbath I

Authors: Briol D, Cerrati A, Annet L, Danse E,

Keywords: SIRT, liver metastases, Prognostic factor, safety,

#3614 Endoscopic ultrasound-guided radiofrequency ablation versus surgical resection for the treatment of pancreatic insulinoma – A multicenter propensity score-matched study

Introduction: EUS-guided radiofrequency ablation (EUS-RFA) is emerging as safe and effective treatment for pancreatic neoplasms.

Conference:

Presenting Author:

Authors: Crinò S, Napoleon B, Lakhtakia S, Borbath I, Caillol F,

Keywords: Endoscopy, enucleation, hypoglycaemia,

#3520 Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial

Introduction: TGR has been investigated as a potential biomarker for antitumor drug activity in NETs.

Conference:

Presenting Author:

Authors: Dromain C, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Tumor Growth Rate, Lanreotide Autogel, midgut, pancreatic,